Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122323) titled 'A randomized double-blind controlled multi-center Phase II/III Clinical Study to Evaluate the Efficacy and Safety of OB756 versus Hydroxyurea in Patients with Intermediate- or High-Risk Myelofibrosis' on April 12.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine
Condition:
Intermediate- to High-Risk Myelofibrosis
Intervention:
OB756:20mg per dose, twice a day
Recruitment Status: Not Recruiting
Phase: 2-3
Date of First Enrollment: 2021-09-08
Target Sample Size: OB756:86;Hydroxyurea:43;
Countries of Recr...